pharmaceutical-investing Auris Medical Closes Two US Patent Acquisitions Related to the Use of Betahistine for the Treatment of Depression and ADHD
pharmaceutical-investing Auris Medical Receives FDA Guidance at Type C Meeting for AM-111 in the Treatment of Sudden Sensorineural Hearing Loss
